Liver Oncology

Gastrointestinal Oncology

Genitourinary Oncology

Lymphoma

Neuroendocrine Tumors

GI and HCC Oncology nursing
The Connects

Learn more about the connect groups
on theconnects.info

Educational Programmes

The Educational Programmes on this page cover the following items:

Useful resources

The SHARE Communication Framework for mCRPC COMING SOON

SHARE provides a simple 5-step approach aimed at improving outcomes through engaging patients with metastatic castration resistant prostate cancer (mCRPC) in their own treatment decision. Educational videos will help you quickly apply the SHARE Communication Framework and move towards even better patient conversations.

Go to Programme

Advanced PET Imaging in Prostate Cancer

Dr. Phillip J. Koo provides his thoughts on the use of advanced PET imaging in prostate cancer

Go to Programme

Adjuvant Therapy in mRCC

This month Prof. Sandy Srinivas and Dr. Roberto Iacovelli provide their thoughts and views on: Adjuvant Therapy in mRCC

Go to Programme

Immunotherapy in genitourinary tumors

This month Prof. Sandy Srinivas and Prof. David Pfister provide an interesting overview of Immunotherapy in genitourinary tumors.

Go to Programme

GU CONNECT Update from…

ESMO 2019

GU CONNECT Update from ESMO 2019

GU CONNECT has summarised highlights of the recent ESMO 2019 meeting for you

Go to Programme

ASCO 2019

GU CONNECT Update from ASCO 2019

GU CONNECT has summarised the highlights from ASCO 2019 for you

Go to Programme

Update from ASCO GU 2019

GU CONNECT has summarised the highlights of the recent ASCO GU 2019 meeting for you.

Go to Programme

ESMO 2018

GU CONNECT Update from ESMO 2018

GU CONNECT has summarised the highlights from ESMO 2018 for you.

Go to Programme

ASCO GU 2018

Update from San Francisco 2018

GU CONNECT has summarised the highlights of the recent ASCO GU 2018 meeting for you.

Go to Programme

ESMO 2017

A CONNECT Update from Madrid

GU CONNECT has summarised the highlights of ESMO September 2017 for you along with the other CONNECT groups.

Go to Programme

ASCO GU 2017

GU CONNECT update from Orlando

GU CONNECT has summarised the highlights of the recent congress of the American Society of Clinical Oncology GU (ASCO GU) 2017 in Orlando, USA for you

Go to Programme

ESMO 2016

GU CONNECT update from Copenhagen

GU CONNECT has summarised the highlights of the recent congress of the European Society for Medical Oncology (ESMO) 2016 in Copenhagen, Denmark for you.

Go to Programme

Your clinical questions answered

Please submit your clinical topic for the next GU CONNECT newsletter here.

New therapies for metastatic hormone sensitive prostate cancer

As an experienced urologist and member of GU CONNECT, Prof. David Pfister provides his perspective on new therapies for mHSPC.

Go to Programme

Treating Oligometastatic Prostate Cancer

Assoc. Prof. Tanya B. Dorff looks into the use of imaging along with the treatment of oligometastatic prostate cancer

Go to Programme

Newly defined criteria for “platinum-ineligible” patients with metastatic urothelial cancer (mUC)

Asst. Prof. Shilpa Gupta discusses the newly defined criteria for “platinum-ineligibility” in patients with metastatic urothelial cancer on behalf of the Platinum-Ineligibility in Bladder Cancer Working Group.

Go to Programme

An update on the treatment of patients with mCRPC with RA-223 plus AAP

Dr. Tia Higano provides her perspective on ERA 223: A phase 3 trial of Ra-223 in combination with AAP in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant mCRPC

Go to Programme

Advances in metastatic hormone-sensitive prostate cancer

Associate Professor Alicia Morgans provides her thoughts on the recent advances in metastatic hormone-sensitive prostate cancer

Go to Programme

How to use combination, sequential and immuno-oncology therapies in mCRPC?

Professor of Medicine Evan Yu and Associate Professor Tanya Dorff provide their thoughts and views on combination, sequential and immuno-oncology therapies in mCRPC (Metastatic Castration-Resistant Prostate Cancer)

Go to Programme

An update on recent cutting-edge trials: Treatments now available for newly diagnosed mHSPC patients

Dr. Neal Shore, Assoc. Prof. Neeraj Agarwal and Prof. Steven Joniau provide their thoughts and views on treatments for newly diagnosed mHSPC (Metastatic Hormone Sensitive Prostate Cancer) patients following recent cutting-edge trials.

Go to Programme

Relevant papers discussed